Australian Building Stock News

Why Computershare is on investors’ radar today With no single headline event driving Computershare (ASX:CPU) today, the focus is on how its current share price of A$28.99 lines up against its recent returns and underlying business profile. See our latest analysis for Computershare. Recent trading has been weak, with a 1-day share price return of a 1.06% decline and a 30-day share price return of a 10.25% decline at A$28.99, while the 5-year total shareholder return of 129.24% highlights how...

In early March 2026, Telix Pharmaceuticals reported that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer met its primary safety and dosimetry objectives, with an acceptable tolerability profile and no new safety signals across combinations with standard-of-care therapies. A distinctive aspect for investors is that TLX591-Tx’s antibody-based design showed minimal kidney, salivary and lacrimal gland exposure versus existing...

Downer EDI Limited has continued its on‑market share buy-back in recent months, repurchasing more than 9.29 million shares as part of its previously announced capital management program, according to past ASX filings up to March 2026. This sustained buy-back effort is materially shrinking the share count, which can influence earnings per share and the ownership mix for remaining investors. We’ll now examine how Downer EDI’s ongoing on‑market buy-back program may influence its investment...

In recent months, Vault Minerals has continued its on-market share buy-back program, with cumulative repurchases surpassing 5.8 million ordinary shares as of 12 March 2026. This ongoing reduction in share count offers investors fresh insight into the company’s capital management priorities and evolving ownership structure. We’ll now examine how Vault Minerals’ ongoing on-market share buy-back activity shapes its investment narrative and potential capital allocation appeal. Outshine the...

Sonic Healthcare, one of the world’s largest pathology providers, has recently attracted fresh attention as its current valuation sits below its historical average price-to-sales ratio despite a period of revenue growth and weaker profit outcomes over the past three years. This mix of apparent value and profitability pressure is prompting investors to reassess whether the company’s scale and service mix can offset its recent challenges. We’ll now examine how Sonic Healthcare’s apparent...

Aristocrat Leisure (ASX:ALL) has drawn investor attention after director Natasha Chand increased her direct shareholding and the company reported further progress in its ongoing on market share buy back program. See our latest analysis for Aristocrat Leisure. Those insider moves come after a tough stretch for the stock, with a 30 day share price return of 13.21% and a year to date share price return of 20.22%. The 1 year total shareholder return of 30.42% contrasts with 3 and 5 year total...

Helia Group recently reported strong FY25 results, including higher net profit and a solid capital position, and its shares have now traded ex-dividend ahead of a large final fully franked dividend and a partially franked special dividend that together reflect a 14% cash yield before franking. By fully paying out statutory NPAT while also shrinking its capital base, Helia is leaning heavily into capital return, raising fresh questions about how it balances near-term income for shareholders...

If you are wondering whether Commonwealth Bank of Australia (CBA) is priced fairly or carrying a premium at around A$171.60 per share, you are not alone. Many investors are asking the same question right now. CBA's share price has been relatively steady over the past week with a 0.6% decline, while the stock shows returns of 8.1% over 30 days, 6.5% year to date, 22.6% over 1 year, 99.5% over 3 years and 140.0% over 5 years. Recent news coverage around CBA has largely focused on its role as a...

Lynas Rare Earths (ASX:LYC) is back on investor radars after extending its supply agreement with Japan Australia Rare Earths to 2038, adding price floors, upside sharing, and renewed Malaysian operating certainty. See our latest analysis for Lynas Rare Earths. The extended JARE deal and Malaysian licence renewal have arrived alongside strong momentum, with a 30 day share price return of 39.83% and a year to date share price return of 73.24%. The 1 year total shareholder return of 191.60% and...

In recent days, Whitehaven Coal has secured stable credit ratings from S&P, Fitch and Moody’s to refinance a major acquisition loan and has continued its on‑market share buy-back, repurchasing more than one million shares as part of its capital management program. Together, the stronger credit profile and active buy-back point to a company placing greater emphasis on funding flexibility, balance sheet strength and shareholder returns. We’ll now examine how Whitehaven’s new credit ratings,...

CSL has recently broken ground on a US$1.50 billion expansion of its Kankakee, Illinois plasma-therapy manufacturing facility, adding at least 300 new pharmaceutical jobs and incorporating its patented Horizon 2 process to increase immunoglobulin and albumin production capacity by 2031. This large-scale build-out not only deepens CSL’s U.S. manufacturing footprint but also advances its goal of end-to-end plasma processing within the United States, which may be important for supply resilience...

Fortescue has commenced construction of its 440MW Solomon Airport solar project in the Pilbara, set to become Western Australia’s largest solar farm and a core element of its Real Zero decarbonisation plans, with completion targeted for 2028 and about 671,000 panels installed. This large-scale solar build signals Fortescue’s push to reduce reliance on traditional fuels at its mining operations while expanding its renewable energy footprint alongside iron ore. We’ll now examine how this major...

Origin Energy in focus after oil price spike The recent surge in oil prices above US$100 per barrel has sharpened attention on Origin Energy (ASX:ORG), given its 27.5% interest in the Australia Pacific LNG project and exposure to higher LNG pricing. See our latest analysis for Origin Energy. Despite the latest share price of A$11.59 and a 1-day share price return decline of 0.34%, Origin’s 30-day share price return of 5.46% and 1-year total shareholder return of 19.41% suggest momentum has...

China Mineral Resources Group has widened its ban on BHP's iron ore, now blocking Newman fines shipments to Chinese steel mills. The move intensifies contract talks and touches BHP's core iron ore revenue base at a sensitive moment for seaborne pricing. Separately, BHP is in advanced talks to sell its West Musgrave copper nickel project, with South32 reported as a leading bidder. These developments point to a possible reshaping of ASX:BHP's exposure to China and to future-facing metals such...

Australian Strategic Materials (ASX:ASM) has just posted its H1 2026 scorecard, with trailing 12 month revenue of A$10.1 million and a net loss of A$21.6 million, translating to a basic EPS loss of A$0.11. Over recent half year periods the company has seen revenue move from A$1.96 million in H2 2024 to A$2.20 million in H1 2025 and A$2.89 million in H2 2025, while basic EPS losses shifted from A$0.10 to A$0.08 and then A$0.06, setting up a results story where investors are weighing growing...

Elsight (ASX:ELS) is back on investor radars after securing a US$21.2 million contract with a European defence drone manufacturer. This development is supported by new senior hires and early deliveries of its Aura communications device. See our latest analysis for Elsight. The contract news and senior hires come after a strong run in Elsight’s shares, with a 49.5% 30 day share price return and a 1 year total shareholder return that is well into double digit multiples. This indicates strong...

Liontown Resources (ASX:LTR) has put fresh numbers on the table for H1 2026, with second half 2025 revenue at A$197.2 million and a basic EPS loss of A$0.077 per share, while trailing twelve month figures to the same point show revenue of A$297.6 million and a basic EPS loss of A$0.080. The company has seen revenue move from A$100.4 million in the first half of 2025 to A$197.2 million in the second half, alongside a shift in basic EPS from an A$0.006 loss in H1 2025 to an A$0.077 loss in H2...

If you are wondering whether Westgold Resources is still good value after its recent run, this article explains what the current share price could mean for long term investors. The stock last closed at A$6.21, with a 14% decline over the past week and a 13% decline over the past month, set against a 137.1% return over the last year and a very large 3 year return that is close to 5x. Recent market attention on Westgold Resources has been shaped by ongoing interest in gold producers and how...

Mesoblast (ASX:MSB) has drawn fresh attention after appointing Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a move that coincides with its upcoming Bell Potter Healthcare Horizons Summit presentation. See our latest analysis for Mesoblast. The recent appointment and upcoming summit appearance come after a tougher stretch for the share price, with a 30 day share price return of 14.4% and a 90 day share price return of 22.74%. However, the 3 year total...

Half year loss widens as investors assess IperionX's progress IperionX (ASX:IPX) has drawn attention after reporting a half year net loss of US$34.77 million for the period to December 31, 2025, compared with US$16.24 million a year earlier. Basic and diluted loss per share from continuing operations came in at US$0.10, versus US$0.06 in the prior comparable period. This gives shareholders fresh data to weigh against the company’s titanium and critical minerals ambitions. See our latest...

Pantoro Gold recently reported higher first-half FY26 revenue and earnings from its Norseman Gold Project in Western Australia, while also cutting full-year production guidance after severe weather and operational disruptions. At the same time, the company outlined plans to expand Norseman with a third underground mine and additional drilling, signalling a push to diversify and grow its production base despite current setbacks. Next, we’ll explore how the guidance downgrade amid plans for a...

Ora Banda Mining recently reported past half-year results to 31 December 2025, highlighting record gold production of 62,631 ounces and a sharp lift in sales to A$336.28 million alongside higher net income and earnings per share. The company also unveiled a tenfold resource increase at its Round Dam deposit, lifting its global resource base to 3.3 million ounces and underlining the scale of its growth ambitions around the Davyhurst project. Next, we’ll examine how the Round Dam resource...

Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing its Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA for prostate cancer recurrence has recruited more participants than originally planned in the US and Australia. See our latest analysis for Clarity Pharmaceuticals. The AMPLIFY recruitment update and recent conference appearance follow a mixed earnings release and a period of strong share price momentum, with a 30 day share price return of 15.90% and a 1 year total shareholder...

S&P Dow Jones Indices recently announced that Lindian Resources will be added to the All Ordinaries index from 23 March 2026, following a period of strong market interest highlighted by technical uptrend screenings and recent acquisition discussions. This combination of index inclusion, momentum-focused research attention and active corporate activity could reshape how investors assess Lindian Resources within the Australian mining sector. We’ll now look at how inclusion in the All...